ScholarLens Back to search
1980•PubMedRequires access

Diethylstilbestrol di-trimethylacetate (DSTMA). A long-acting estrogen.

Noland Jl, M A Amin

Open publisher page 0 citations

Abstract

A series of estradiol and diethylstilbestrol (DES) esters was prepared as part of a study of the structure-activity relations in estrogens. Among the esters tested, DES di-trimethylacetate (DSTMA) exhibited the most favorable combination of a low minimum-effective dose and prolongation of effect in all experimental groups (mice, rats, dogs). Toxicity of DSTMA was low. A clinical trial in four stage III and stage IV prostatic cancer patients showed that dosage levels of DSTMA as high as 75 mg per day for short periods were well tolerated and no toxic symptoms attributable to the estrogen itself were observed.

About this research paper

What this paper is about

A series of estradiol and diethylstilbestrol (DES) esters was prepared as part of a study of the structure-activity relations in estrogens. Among the esters tested, DES di-trimethylacetate (DSTMA) exhibited the most favorable combination of a low minimum-effective dose and prolongation of effect in all experimental groups (mice, rats, dogs). Toxicity of DSTMA was low. A clinical trial in four stage III and stage IV prostatic cancer patients showed that dosage levels of DSTMA as high as 75 mg per day for short periods were well tolerated and no toxic symptoms attributable to the estrogen itself were observed.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A series of estradiol and diethylstilbestrol (DES) esters was prepared as part of a study of the structure-activity relations in estrogens. Among the esters tested, DES di-trimethylacetate (DSTMA) exhibited the most favorable combination of a low minimum-effective dose and prolongation of effect in all experimental groups (mice, rats, dogs). Toxicity of DSTMA was low. A clinical trial in four stage III and stage IV prostatic cancer patients showed that dosage levels of DSTMA as high as 75 mg per day for short periods were well tolerated and no toxic symptoms attributable to the estrogen itself were observed.

Key concepts: Diethylstilbestrol, Estrogen, Medicine, Toxicity, Internal medicine, Endocrinology, Physiology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Diethylstilbestrol di-trimethylacetate (DSTMA). A long-acting estrogen. — Research Paper | ScholarLens